GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 274,717 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.50, for a total transaction of $961,509.50. Following the completion of the transaction, the insider directly owned 777,213 shares of the company’s stock, valued at approximately $2,720,245.50. The trade was a 26.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Francisco Partners Iv, L.P. also recently made the following trade(s):
- On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The stock was sold at an average price of $3.52, for a total value of $1,574,351.68.
- On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75.
GoodRx Stock Performance
GDRX opened at $3.45 on Friday. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of 86.27, a P/E/G ratio of 1.77 and a beta of 1.60. The business’s 50-day moving average price is $3.13 and its two-hundred day moving average price is $2.63. GoodRx Holdings, Inc. has a 1 year low of $1.77 and a 1 year high of $5.81. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38.
Institutional Trading of GoodRx
Several institutional investors and hedge funds have recently added to or reduced their stakes in GDRX. Headlands Technologies LLC acquired a new stake in GoodRx in the second quarter valued at $30,000. Technology Crossover Management X Ltd. acquired a new position in shares of GoodRx during the 2nd quarter worth about $4,762,000. Bank of New York Mellon Corp acquired a new position in shares of GoodRx during the 2nd quarter worth about $540,000. Essential Partners LLC raised its holdings in shares of GoodRx by 375.4% in the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after purchasing an additional 11,295 shares during the period. Finally, Amundi bought a new stake in shares of GoodRx in the 1st quarter valued at about $37,000. 63.77% of the stock is owned by institutional investors.
Analyst Ratings Changes
GDRX has been the subject of several research reports. Weiss Ratings raised shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. Wall Street Zen raised shares of GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. The Goldman Sachs Group restated a “neutral” rating and set a $4.00 target price on shares of GoodRx in a report on Friday, August 7th. Citigroup raised their target price on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Leerink Partners set a $5.00 price target on shares of GoodRx in a research note on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.23.
Check Out Our Latest Stock Report on GoodRx
GoodRx Company Profile
GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.
Featured Stories
- Five stocks we like better than GoodRx
- MarketBeat Week in Review – 08/17 – 08/21
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.
